Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand
AuthorsParker, David C.
Greiner, Dale L.
Phillips, Nancy E.
Appel, Michael C.
Steele, Alan W.
Durie, Fiona H.
Noelle, Randolph J.
Mordes, John P.
Rossini, Aldo A.
UMass Chan AffiliationsDepartment of Medicine, Division of Endocrinology and Metabolism
Department of Medicine, Division of Diabetes
Department of Molecular Genetics and Microbiology
Antigens, Differentiation, T-Lymphocyte
Diabetes Mellitus, Experimental
Islets of Langerhans Transplantation
Mice, Inbred BALB C
Mice, Inbred C3H
Mice, Inbred C57BL
Medicine and Health Sciences
MetadataShow full item record
AbstractCombined treatment with allogeneic small lymphocytes or T-depleted small lymphocytes plus a blocking antibody to CD40 ligand (CD40L) permitted indefinite pancreatic islet allograft survival in 37 of 40 recipients that differed from islet donors at major and minor histocompatibility loci. The effect of the allogeneic small lymphocytes was donor antigen-specific. Neither treatment alone was as effective as combined treatment, although anti-CD40L by itself allowed indefinite islet allograft survival in 40% of recipients. Our interpretation is that small lymphocytes expressing donor antigens in the absence of appropriate costimulatory signals are tolerogenic for alloreactive host cells. Anti-CD40L antibody may prevent host T cells from inducing costimulatory signals in donor lymphocytes or islet grafts.
Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9560-4.